Continued strong performance of RASUVO and RUPAL, which continues to maintain its position as one of the fastest growing antihistamines in its market. And then of course, there's Gluoland, which we started selling during the Q4 last fiscal year before Successfully completing our agreed transition period this past August. Gross profit has also increased for both periods and was $15,000,000 60,000,000 for the 3 12 month periods ended March 31, 2022, respectively, compared to gross profit of $10,100,000 $37,900,000 for the same periods in the previous year. The gross margin was 52.4% 55.5% For the 3 12 months period ended March 31, 2022, respectively, compared to 49.8% 49.4% for the 3 and 12 months period ended March 31, 2022. Selling and administrative expenses were 11,400,000 and $48,300,000 for the 3 12 months period ended March 31, 2023, compared to 9,900,000 and $44,000,000 for the 3 12 months period ended March 31, 2022.